YM BioSciences

YM-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about YM-T

Signal
Opinion
Expert
TOP PICK
TOP PICK
March 26, 2008
Recently suffered when phase 3 testing failed. Has cash in the bank, has a long runway (cash on a burn rate). Have 2 products in phase 3, one of which is approved in India and China. Great opportunities. Way undervalued.
Show full opinionHide full opinion
YM BioSciences (YM-T)
March 26, 2008
Recently suffered when phase 3 testing failed. Has cash in the bank, has a long runway (cash on a burn rate). Have 2 products in phase 3, one of which is approved in India and China. Great opportunities. Way undervalued.
BUY
BUY
May 24, 2007
In spite of its setback, he still likes. Risks/reward at this point is not bad. Speculative.
Show full opinionHide full opinion
In spite of its setback, he still likes. Risks/reward at this point is not bad. Speculative.
DON'T BUY
DON'T BUY
February 19, 2007
Was forced to cancel its cancer treatment trial. They do have some cash. Have another product in the pipeline, but it is in Cuba, which will keep US investors away.. It will take 6 months for the market to care again.
Show full opinionHide full opinion
YM BioSciences (YM-T)
February 19, 2007
Was forced to cancel its cancer treatment trial. They do have some cash. Have another product in the pipeline, but it is in Cuba, which will keep US investors away.. It will take 6 months for the market to care again.
BUY
BUY
January 24, 2007
Tesmilifene is the 1st compound they’ll have pivotal phase 3 results on and the stock should move up strongly. Behind that, Nimotuzumab is a great compound that has some interesting phase 2 trials. Great risk/reward.
Show full opinionHide full opinion
YM BioSciences (YM-T)
January 24, 2007
Tesmilifene is the 1st compound they’ll have pivotal phase 3 results on and the stock should move up strongly. Behind that, Nimotuzumab is a great compound that has some interesting phase 2 trials. Great risk/reward.
BUY
BUY
September 7, 2006
The only biotech stock that he owns. Accumulates on weakness. Had 2 trials on their cancer drug without getting approval, but this isn't a concern. Statistically difficult to get approval in 2 tries. Is expecting a successful end point. Have a fantastic pipeline of other drugs as well.
Show full opinionHide full opinion
YM BioSciences (YM-T)
September 7, 2006
The only biotech stock that he owns. Accumulates on weakness. Had 2 trials on their cancer drug without getting approval, but this isn't a concern. Statistically difficult to get approval in 2 tries. Is expecting a successful end point. Have a fantastic pipeline of other drugs as well.
Showing 1 to 5 of 5 entries
  • «
  • 1
  • »